Zelira Therapeutics Ltd has released a press release.
Zenivol receives formal BfArM approval in Germany
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Story so far
Earlier from Zelira Therapeutics
- Pause in Trading
- EDCDM Technology License Agreement Update
- Zenivol Longitudinal, RWD Trial in Insomnia Results
- Hope 1 Longitudinal, Real-World Data Trial in ASD Results
- March 2022 Quarterly Activities Report
Later from Zelira Therapeutics
- June 2022 Quarterly Activities Report
- Response to ASX Aware Query
- ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled
- September 2022 Quarterly Activities Report
- ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics